SCHEMBL5569389

SCHEMBL5569389

CCc1cc(CCCc2ccc(C(=O)OC)c(C(=O)OC)c2)ccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.51
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
ALOX15 P16050 2/20 0.46
HSD17B10 Q99714 2/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX12 P18054 1/20 0.46
CYP2C19 P33261 1/20 0.46
CKS1B P61024 1/20 0.46
SKP2 Q13309 1/20 0.46
HIF1A Q16665 1/20 0.46
KAT8 Q9H7Z6 2/20 0.46
EGFR P00533 4/20 0.43
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565669 0.84 ESR1 (0.45) ALDH1A1HPGDALOX15HSD17B10TP53
SCHEMBL5595846 0.82 BACE1 (0.72) BACE1ALOX15KAT8ALOX5
SCHEMBL5570240 0.81 KAT8 (0.60) BACE1ALOX15KAT8EGFRPPARA
SCHEMBL28773091 0.81 PPARA (0.58) ALDH1A1HPGDALOX15HSD17B10KAT8
SCHEMBL13332007 0.80 ALDH1A1 (0.56) ALDH1A1HPGDALOX15HSD17B10CA12
SCHEMBL20725428 0.80 KAT8 (0.61) ALDH1A1HPGDALOX15HSD17B10CYP1A2
SCHEMBL22907008 0.79 CYP4A11 (0.63) ALDH1A1HPGDALOX15HSD17B10CA12
SCHEMBL5565295 0.79 ALDH1A1 (0.41) ALDH1A1HPGDALOX15HSD17B10PPARA
SCHEMBL26270868 0.79 MAPT (0.51) ALDH1A1HPGDALOX15HSD17B10CA12
SCHEMBL22032168 0.78 CYP4A11 (0.58) ALDH1A1HPGDALOX15HSD17B10CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312249-B2 Vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-12-25 US disclosed
EP-1537065-B1 ANALOGUES OF VITAMIN D GALDERMA RES & DEV (FR) 2006-11-02 EP disclosed
US-20050182144-A1 Novel vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-18 US disclosed
EP-1537065-A1 ANALOGUES OF VITAMIN D Galderma Research & Development, S.N.C. (FR) 2005-06-08 EP disclosed
WO-2004020379-A1 ANALOGUES OF VITAMIN D GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182144-A1 Novel vitamin D analogues CYP24A1, CYP2R1, VDR BACE1 1060/4885ALDH1A1 121/4885HPGD 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.